Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Pharmingen
Profile last edited on: 12/23/14      CAGE:       UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
1987
First Award
1988
Latest Award
1995
Program Status
Inactive (Acquired)
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

10975 Torreyana Road
San Diego, CA 92121
   (619) 812-8800
   info@pharmingen.com
   www.pharmingen.com
Location: Single
Congr. District: 52
County: San Diego

Public Profile

In May 1997, PharMingen was acquired by Becton Dickinson & Company, Pharmingen develops and manufactures monoclonal antibodies and products in immunology, cell biology and cancer biology fields, baculovirus and other protein expression systems.

Extent of SBIR involvement

User Avatar
Phase I Awards
6
Phase II Awards
1
Conversion Rate
16.67%
Phase I Dollars
$349,447
Phase II Dollars
$494,357
Total Awarded
$843,804

Synopsis: Awardee Business Condition

Employee Range
250-500
Revenue Range
20M-50M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
1995 1 NIH $99,447
Project Title: mAbs for Detection of E2a/Pbxl Fusion Proteins in All
1993 1 NIH $50,000
Project Title: Mars Specific to Human MyoD Protein
1993 1 NIH $50,000
Project Title: Anti-androgen receptor MABs for human prostate cancer
1992 1 NIH $50,000
Project Title: MABs to tumor spressor gene DCC-encoded protein
1991 1 NIH $50,000
Project Title: MABS specific to human tumor supressor protein P53

Key People / Management

  Ernest Huang -- President

  Stefan Gruenwald

  Chiu-Yang Shih

Company News

There are no news available.